Handelsbanken Fonder Ab Seagen Inc. Transaction History

Handelsbanken Fonder Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$191.51 - $216.16 $542,356 - $612,165	2,832 Added 4.62%	64,096 $13.6 Million
Q2 2023 Aug 02, 2023	BUY	$187.64 - $206.25 $1.53 Million - $1.68 Million	8,149 Added 15.34%	61,264 $11.8 Million
Q1 2023 Apr 28, 2023	BUY	$127.59 - $203.08 $404,843 - $644,372	3,173 Added 6.35%	53,115 $10.8 Million
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $3.77 Million - $4.47 Million	-32,145 Reduced 39.16%	49,942 $6.42 Million
Q2 2022 Aug 03, 2022	BUY	$108.81 - $179.33 $3.34 Million - $5.5 Million	30,671 Added 59.65%	82,087 $14.5 Million
Q1 2022 May 11, 2022	BUY	$119.61 - $157.85 $74,277 - $98,024	621 Added 1.22%	51,416 $7.41 Million
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $5.14 Million - $6.88 Million	36,066 Added 244.86%	50,795 $7.85 Million
Q2 2021 Aug 03, 2021	SELL	$135.08 - $161.1 $2.38 Million - $2.84 Million	-17,604 Reduced 54.45%	14,729 $2.33 Million
Q1 2021 Apr 29, 2021	BUY	$137.51 - $190.8 $349,962 - $485,586	2,545 Added 8.54%	32,333 $4.49 Million
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $4.9 Million - $6.31 Million	29,788 New	29,788 $5.22 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.